ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "interstitial lung disease"

  • Abstract Number: 2074 • ACR Convergence 2025

    Increased Mortality in Hispanic Males with Lymphopenia: A Descriptive and Statistical Analysis of Anti-Melanoma Differentiation-Associated Protein 5 (MDA-5) Antibody Positive Patients

    Sergio Maldonado Chaar1 and Kelly Corbitt2, 1University of Miami/Jackson Health, Miami, FL, 2University of Miami Miller School of Medicine, El Portal, FL

    Background/Purpose: Anti-melanoma differentiation-associated protein 5 (MDA-5) antibody positivity in dermatomyositis (DM) is often associated with development of interstitial lung disease (ILD), with factors such as…
  • Abstract Number: 1862 • ACR Convergence 2025

    Comprehensive analysis of the major histocompatibility complex in systemic sclerosis-associated interstitial lung disease identifies novel associated loci and potential progression biomarkers

    Carlos de la Rosa Báez1, Carlos Rangel Peláez1, Inmaculada Rodríguez Martín1, Martin Kerick1, Alfredo guillen-del-castillo2, Carmen Pilar Simeon3, Jose Luis Callejas4, Alexandre Voskuijl5, Alexander Kreuter6, Oliver Distler7, Susanna Proudman8, Mandana Nikpour9, Nicolas Hunzelmann10, Jeska de Vries-Bouwstra11, Ariane Herrick12, Yannick Allanore13, Lorenzo Beretta14, Maureen Mayes15, Christopher Denton16, Shervin Assassi17, Javier Martin1 and Marialbert Acosta-Herrera1, 1Department of Cell Biology and Immunology, Institute of Parasitology and Biomedicine López-Neyra, CSIC, Granada, Spain, 2Unit of Autoimmune Diseases, Department of Internal Medicine, Hospital Universitario Vall d’Hebron, Barcelona, Spain, 3Department of Internal Medicine, Hospital Universitario Vall d’Hebron, Barcelona, Spain, 4Department of Internal Medicine, Hospital San Cecilio, Granada, Spain, 5Amsterdam University Medical Center, Amsterdam, Netherlands, 6Department of Dermatology, Venereology, and Allergology, Helios St. Elisabeth Klinik Oberhausen, University Witten-Herdecke, Oberhausen, Germany, 7Department of Rheumatology, University Hospital Zurich, University of Zurich, Switzerland, Zurich, Switzerland, 8Royal Adelaide Hospital and University of Adelaide, Medindie, South Australia, Australia, 9University of Sydney School of Public Health and Department of Rheumatology, Royal Prince Alfred Hospital, Sydney, Victoria, Australia, 10Department of Dermatology and Venereology, University Hospital Cologne, Cologne, Germany, 11Leiden University Medical Center, Leiden, Netherlands, 12The University of Manchester, UK, Aberdeen, United Kingdom, 13Department of Rheumatology, Université Paris Cité UFR de Médecine, Paris, France, 14Referral Center for Systemic Autoimmune Diseases, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy, 15UT Health Houston Division of Rheumatology, Houston, TX, 16University College London, UK, London, United Kingdom, 17Division of Rheumatology, UTHealth Houston, Houston, Texas, USA, Houston, TX

    Background/Purpose: The main causes of death in systemic sclerosis (SSc) are pulmonary complications such as SSc-associated interstitial lung disease (SSc-ILD). SSc-ILD is highly heterogeneous and…
  • Abstract Number: 1577 • ACR Convergence 2025

    Intravenous cyclophosphamide in the treatment of progressive interstitial lung diseases associated with systemic sclerosis: a prospective randomized trial versus placebo (SCLEROCYC).

    Luc Mouthon1, David Launay2, Sylvie leroy3, Christian AGARD4, Yannick Allanore5, Alice berezne1, Emmanuel Bergot6, Boris Bienvenu7, Benjamin Chaigne1, Pascal Cohen8, Bruno Crestani9, Anca Corondan10, bertrand Dunogue1, Christian Lavigne11, Jonathan London12, Jean-Marc Naccache10, Gabriel Baron13, Alexis REGENT14, Benjamin Terrier15, Zahir AMOURA16, Charles Marquette10 and Philippe Ravaud13, 1Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Cochin University Hospital, Université Paris Cité, AP-HP, Paris, France, 2Univ. Lille, Inserm, CHU Lille, Department of Internal Medicine and Clinical Immunology, Reference Center for Rare Autoimmune and Autoinflammatory diseases (CERAINOM), U1286 - INFINITE - Institute for Translational Research in Inflammation, Lille, France. National Reference Center for Pulmonary Arterial Hypertension (Pulmotension), Lille, France, Lille Cedex, France, 3AP HP, Paris, France, 4Internal medicine, Nantes University Hospital, Nantes, France, 5Université Paris Cité, Paris, France, 6CHU, Caen, France, 7Saint Joseph Hospital, Marseille, France, 8Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hospital Cochin, Paris, France, 9CHU, Paris, France, 10NA, Paris, France, 11CHU, Angers, France, 12Hôpital Croix-Saint-Simon, Paris, France, 13Hôtel-Dieu, Université Paris Cité,, Paris, France, 14Hopital Cochin, Paris, France, 15Cochin Hospital, Paris, France, 16APHP, Paris, France

    Background/Purpose: Interstitial lung disease (ILD) is the leading cause of death in patients with systemic sclerosis (SSc). Randomized controlled trials favoured the use of cyclophosphamide…
  • Abstract Number: 1255 • ACR Convergence 2025

    Lung Transplantation Outcomes for Pulmonary Sarcoidosis Compared to Idiopathic Pulmonary Fibrosis: A Single Institution Multisite Experience

    Reena Yaman1, Lisa Balistreri2, Maximiliano Diaz Menindez3, Sehreen Mumtaz1, Megan Sullivan3, Alexander Hochwald1 and Florentina Berianu1, 1Mayo Clinic Florida, Jacksonville, FL, 2Lee Health, Cape Coral, FL, 3Mayo Clinic Arizona, Scottsdale, AZ

    Background/Purpose: Pulmonary disease is present in most sarcoidosis cases with up to 10% of patients progressing to advanced lung disease.1 Pulmonary sarcoidosis accounted for 2.5%…
  • Abstract Number: 1063 • ACR Convergence 2025

    Gender, Racial, and Geographic Trends in Mortality from Interstitial Lung Diseases Among Patients With Rheumatoid Arthritis in the U.S. Population, 1999–2020

    Farheen Malik1, Jawad Ahmed2, Mandar Shah1, Ritika Uttam3 and Muhammad Fahimuddin1, 1Jacobi Medical Center, Bronx, NY, NY, 2Northwest Health Porter, Valpraiso, IN, 3Jacobi Medical Center, Bronx, NY

    Background/Purpose: Rheumatoid arthritis (RA) is a common autoimmune disease affecting up to 1.0% of the US population. RA is most commonly associated with synovial inflammation…
  • Abstract Number: 0465 • ACR Convergence 2025

    Reproductive Factors and Risk of Rheumatoid Arthritis-Associated Interstitial Lung Disease or Bronchiectasis in Women

    Suchita Nety1, Xiaosong Wang2, Misti Paudel3, Ying Qi4, Qianru Zhang1, Nancy Shadick5, Michael Weinblatt6, Liya Sisay Getachew7, Gregory McDermott8 and Jeffrey Sparks7, 1Harvard Medical School, Boston, MA, 2Brigham and Women's Hospital, Natick, MA, 3Brigham and Women's Hospital, Division of Rheumatology, Inflammation, and Immunity, Boston, MA, 4Brigham and Women’s Hospital, Boston, 5Brigham & Women's Hospital, Boston, MA, 6Brigham and Women's Hospital/ Harvard Medical School, Waban, MA, 7Brigham and Women's Hospital, Boston, MA, 8Brigham and Women's Hospital, Brookline, MA

    Background/Purpose: RA-associated lung diseases (RA-LD) such as RA-associated interstitial lung disease (RA-ILD) and RA-associated bronchiectasis (RA-BR) are more common in men, but risk rises with…
  • Abstract Number: 2299 • ACR Convergence 2025

    Real-world clinical effectiveness of rituximab rescue therapy in patients with progressive interstitial lung disease associated with primary sjögren’s syndrome

    Paula Estrada-Alarcón1, Delia Reina2, JUAN JOSE ALEGRE SANCHO3, Montserrat Roig Kim4, martí Aguilar-Coll5, Laia De Daniel Bisbe4, Aina Fabregat5, Monica Cubells5 and Javier Narváez6, 1Hospital de San Juan Despí Moisès Broggi, Barcelona, Spain, 2Complex Hospitalari Universitari Moisès Broggi, Barcelona, Spain, 3Department of rheumatology. Hospital Universitario Doctor Peset, Valencia, Spain, 4Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Spain, 5Hospital Universitari de Bellvitge, Barcelona, Spain, 6Hospital Universitario de Bellvitge, Barcelona, Spain

    Background/Purpose: To evaluate the real-world, long-term effectiveness of rituximab (RTX) as rescue therapy in patients with primary Sjögren’s syndrome-associated interstitial lung disease (pSS-ILD).Methods: Multicentre observational…
  • Abstract Number: 2050 • ACR Convergence 2025

    Efficacy and Safety of Antifibrotic Therapy in Autoimmune–Associated Interstitial Lung Disease: A Meta-Analysis

    Sri Laxmi Priya Sunkara1, Ravi Medarametla2, Anjani Mahesh Kumar Cherukuri3, Rithish Nimmagadda4, Kaksha Parrikh5, Punith Chirumamilla6, Pranathi Bandarupalli7, Manoja Gullapalli8 and Naga Alekhya Garikipati9, 1White river medical center, batesville, AR, 2Mamata Medical College, Guntur, Andhra Pradesh, India, 3Guntur Medical College, Guntur, Andhra Pradesh, India, 4One Brooklyn Health, New York, NY, 5Atlanticare regional medical center, New Jersey, 6Baptist Memorial Hospital North Mississippi, Oxford, MS, 7Mercy St Vincent Medical Center, Toledo, OH, 8University of Arkansas for Medical Sciences, Little Rock, AR, 9Mediciti Institute Of Medical Sciences, Hyderabad, India

    Background/Purpose: Autoimmune–associated interstitial lung disease (A‑ILD) which includes Rheumatoid arthritis associated interstitial lung disease (RA-ILD), Systemic Sclerosis associated interstitial lung disease (SS-ILD), and others is…
  • Abstract Number: 1860 • ACR Convergence 2025

    GLUT and FAPα as molecular imaging markers for interstitial lung disease in systemic sclerosis

    Bo Broens1, Conny van der Laken1, Teodora Radonic1, Douwe Mulder2, esther Nossent1, Yehya Al-Adwi2, Tji Gan2, Wim Timens2, Alexandre Voskuijl3 and Jan Willem Duitman1, 1Amsterdam UMC, Amsterdam, Netherlands, 2UMCG Groningen, Groningen, Netherlands, 3Amsterdam University Medical Center, Amsterdam, Netherlands

    Background/Purpose: The clinical management of systemic sclerosis-associated interstitial lung disease (SSc-ILD) is challenging due to its heterogeneous progression. While recent studies have shown that pulmonary…
  • Abstract Number: 1576 • ACR Convergence 2025

    Impact of COVID-19 Infection on Fibrosis Progression in CTD-Associated ILD: An AI-Based Quantitative CT Study

    kyung-Ann Lee1, Hyun-Sook Kim2 and Boda Nam3, 1Soonchunhyang University Hospital Seoul: Soonchunhyang University Hospital, Seoul, Republic of Korea, 2Soonchunhyang University Seoul Hospital, Seoul, Republic of Korea, 3Chung-Ang University Hospital, Seoul, Republic of Korea

    Background/Purpose: Pulmonary fibrosis is a recognized sequela of severe COVID-19 pneumonia, but its additive impact on pre-existing interstitial lung disease (ILD)—particularly in patients with connective…
  • Abstract Number: 1220 • ACR Convergence 2025

    Predictors of Progressive Pulmonary Fibrosis in Idiopathic Inflammatory Myopathies : a Retrospective Study of 502 Cases

    Wei Bian1, Jian Hao1, Na zhang1, Xiaojing Zhang1, Fumin Qi1, Yin Zhao2 and Wei Wei1, 1Tianjin Medical University General Hospital, Tianjin, China (People's Republic), 2Affiliated Hospital of Yunnan University, Yunnan, China (People's Republic)

    Background/Purpose: Interstitial lung disease (ILD) in idiopathic inflammatory myopathies (IIM) causes worse prognosis. Some patients develop progressive pulmonary fibrosis (PPF) despite appropriate treatment. Identifying predictors…
  • Abstract Number: 1024 • ACR Convergence 2025

    Mortality In Progressive Pulmonary Fibrosis Associated to Autoimmune Diseases: NEREA Registry

    Marta Ruiz-Valdepeñas Almansa1, CLARA DE MIGUEL2, DALIFER FREITES3, Cristina Vadillo Font4, Maria asuncion Nieto4, Olga Sanchez Pernaute5, fredeswinda Romero-Bueno6, Mª Jesus Rodriguez-Nieto7, Rosalia Laporta8, Hilda Godoy Tundidor9, Jesús Loarce10, Juan A Rigual11 and lydia Abasolo Alcazar12, 1HOSPITAL CLINICO SAN CARLOS, Madrid, Spain, 2HOSPITAL CLINICO SAN CARLOS, Madrid, Madrid, Spain, 3Rheumatology Service, San Carlos Clinical Hospital, Madrid, Madrid, Spain, 4Hospital Clínico S Carlos, Madrid, Spain, 5Clinica Universidad de Navarra, Madrid, Madrid, Spain, 6University Hospital Fundación Jiménez Díaz"", Madrid, Spain, 7Fundacion Jimenez Diaz (IIS-HUFJD), Madrid, Spain, 8Hospital Puerta de Hierro Majadahonda, Madrid, Spain, 9Hospital Universitario puerta de hierro, Madrid, Spain, 10HOSPITAL RAMÓN Y CAJAL, MADRID, Madrid, Spain, 11Hospital Ramón y Cajal, Madrid, Spain, 12IdISSC. HCSC, Madrid, Madrid, Spain

    Background/Purpose: Autoimmune interstitial lung disease (ILD) may arise in various autoimmune rheumatic diseases (ARD). Some patients develop ILD with systemic symptoms and autoantibodies without fulfilling…
  • Abstract Number: 0453 • ACR Convergence 2025

    Safety of DMARDs in Rheumatoid Arthritis: A Nationwide Study of ILD Risk and Outcomes in RA-ILD

    kyung-Ann Lee1, Bora Lee2, Hyun-Sook Kim3 and Se Hee Kim4, 1Soonchunhyang University Hospital Seoul: Soonchunhyang University Hospital, Seoul, Republic of Korea, 2Chosun University, GwangJu, Republic of Korea, 3Soonchunhyang University Seoul Hospital, Seoul, Republic of Korea, 4Kyung Hee University College of Medicine, Seoul, Republic of Korea

    Background/Purpose: Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) is a potentially life-threatening extra-articular manifestation of RA. The comparative safety of disease-modifying antirheumatic drugs (DMARDs) in RA…
  • Abstract Number: 2265 • ACR Convergence 2025

    Progressive Interstitial Lung Disease associated to Rheumatoid Arthritis despite Abatacept therapy. Data from a large national multicenter cohort of 526 patients

    Ana Serrano-Combarro1, Belén Atienza-mateo2, Adrian Martin-Gutierrez3, Marta López-Maraver4, Libe Ibarrola5, Ivette Casafont-Solé6, Jesús Loarce7, Juan María Blanco-Madrigal8, Santos Castañeda9, Rafaela Ortega-Castro10, Natalia Mena Vázquez11, Nuria Vegas Revenga12, Lucia C. Domínguez-Casas13, Cilia Peralta-Ginés14, Carlos Fernández Díaz15, Javier Loricera16 and Ricardo Blanco17, 1Division of Rheumatology, Hospital Universitario Marques de Valdecilla, IDIVAL, Inmunopathology group, Santander, Santander, Spain, 2Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, PALMA DE MALLORCA/BALEARES, Spain, 3Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Renedo de Piélagos, Spain, 4Hospital Universitario Araba, Vitoria, Spain, 5Galdakao-Usansolo University Hospital, GALDAKAO, Spain, 6Hospital Universitari Germans Trias i Pujol, Badalona, Spain, 7Ramón y Cajal University Hospital, Madrid, Spain, 8Rheumatology. Hospital Universitario Araba., Vitoria, Pais Vasco, Spain, 9Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Madrid, Spain, 10Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Andalucia, Spain, 11Hospital Regional Universitario de Malaga, Malaga, Spain, Málaga, Spain, 12Galdakao- Usansolo University Hospital, Galdakao, Spain, 13Hospital Universitario San Agustin, Aviles, Spain, Aviles, 14Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain, 15H.U. Santa Lucia, Murcia, Spain, 16Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, 17Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain

    Background/Purpose: Interstitial lung disease (ILD) is a severe extra-articular manifestation of rheumatoid arthritis (RA). Abatacept (ABA) has demonstrated effectiveness in the treatment of RA-ILD, regardless…
  • Abstract Number: 2047 • ACR Convergence 2025

    Trends in Lung Transplant Listing Outcomes in Connective Tissue Disease associated Interstitial Lung Disease (CTD-ILD) Across Two Decades

    Sambhawana Bhandari1, Derek E. Byers1 and Deepali Sen2, 1Washington University in St. Louis School of Medicine, St. Louis, 2Washington University in St Louis, Chesterfield, MO

    Background/Purpose: Lung transplantation represents a potential life-extending therapy for patients with advanced CTD-ILD. This study aims to characterize lung transplant listing outcomes among CTD-ILD patients…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 47
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology